7 recruiting, 2 enrolling by invitation. 8 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Recruiting 6, Enrolling by invitation 2 |
| Phase 1 | 5 | Recruiting 3, Enrolling by invitation 2 |
Follow Paul Szabolcs: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD) Hematopoietic stem cell transplant (HSCT) - Common Variable Immunodeficiency (CVID), Primary Immune Regulatory Disorder | Phase 2 | Recruiting | Paul Szabolcs | 25 | 2026-05-04 | 2026-05-15 |
| Anti-viral T-cell Therapy by Gamma Capture Specific T- Lymphocytes - Adenovirus, Cytomegalovirus Infections | Phase 1 / Phase 2 | Enrolling by invitation | Paul Szabolcs | 25 | 2024-01-08 | 2026-06-29 |
| Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC data collection - Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes | Recruiting | Paul Szabolcs | 50 | 2020-08-20 | 2026-01-13 | |
| T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias CD3/CD19 depleted leukocytes, CD45RA depleted leukocytes, Hydroxyurea - Sickle Cell Anemia, Beta-thalassemia Major | Phase 1 / Phase 2 | Recruiting | Paul Szabolcs | 5 | 2018-08-02 | 2026-08-13 |
| Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis Cyclophosphamide, Mesna, Rituximab - Systemic Sclerosis, Diffuse Sclerosis Systemic | Phase 2 | Recruiting | Paul Szabolcs | 8 | 2018-07-31 | 2026-08-14 |
| Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure CD3/CD19 negative hematopoietic stem cells, Rituximab, Alemtuzumab - Idiopathic Pulmonary Fibrosis, Emphysema or COPD | Phase 1 / Phase 2 | Recruiting | Paul Szabolcs | 8 | 2018-04-19 | 2026-01-13 |
| Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT Hydroxyurea, Alemtuzumab, Fludarabine - Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes | Phase 2 | Recruiting | Paul Szabolcs | 100 | 2014-02-04 | 2025-12-15 |
| Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases CD3/CD19 negative allogeneic hematopoietic stem cells - Severe Combined Immunodeficiency (SCID), Immunodeficiency With Predominant T-cell Defect, Unspecified | Phase 1 / Phase 2 | Enrolling by invitation | Paul Szabolcs | 16 | 2013-06-20 | 2025-12-15 |
| Autologous Stem Cell Transplantation for Crohn's Disease autologous CD34-selected peripheral blood stem cells transplant, Alemtuzumab, ATG - Crohn's Disease | Phase 1 / Phase 2 | Recruiting | Paul Szabolcs | 20 | 2012-06-26 | 2025-12-15 |
Granulomatous Disease, Chronic (4) · Severe Combined Immunodeficiency (4) · Anemia, Diamond-Blackfan (3) · Anemia, Sickle Cell (3) · Crohn Disease (3) · Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked Syndrome (3) · Wiskott-Aldrich Syndrome (3) · beta-Thalassemia (3) · Adrenoleukodystrophy (2) · Autoimmune Lymphoproliferative Syndrome (2) · Chediak-Higashi Syndrome (2) · Common Variable Immunodeficiency (2) · Congenital Bone Marrow Failure Syndromes (2) · Congenital amegakaryocytic thrombocytopenia (2) · Gaucher Disease (2)
Alemtuzumab (5) · Thiotepa (5) · Rituximab (4) · Filgrastim (3) · Hydroxyurea (3) · fludarabine (3) · fludarabine phosphate (3) · Antilymphocyte Serum (2) · Cyclophosphamide (2) · Granulocyte Colony-Stimulating Factor (2) · Melphalan (2) · Mesna (2) · thymoglobulin (2) · Data Collection (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1)
United States (9)